Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Regeneron links 2026 CEO, CSO PSU awards to FDA filings, approvals and new-product revenue targets through 2035

Regeneron links 2026 CEO, CSO PSU awards to FDA filings, approvals and new-product revenue targets through 2035

BitgetBitget2026/09/30 20:14
  • Regeneron set 2026 performance stock units for its CEO and CSO with a 10-year performance window running from Jan. 1, 2026.
  • Earnouts hinge on FDA filing and approval activity through 2034-2035, with additional payouts tied to new-product revenue in 2032-2035.
  • Revenue-based awards start at $10 billion for 250,000 PSUs, rising to 1,800,000 PSUs at $30 billion, with linear interpolation.
  • Total awards are capped at 2,700,000 PSUs for the CEO, 2,900,000 PSUs for the CSO, with additional limits before 2034.
  • A relative TSR modifier of up to ±20% applies versus the Nasdaq Biotechnology Index, with an absolute-TSR floor blocking upward adjustment.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regeneron Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-112340), on September 30, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!